Agenus Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights – AGEN

Core Viewpoint - A class action securities lawsuit has been filed against Agenus Inc. alleging securities fraud that affected investors between January 23, 2023, and July 17, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding the effectiveness of their immuno-oncology combination therapy involving botensilimab and balstilimab, which were overstated [2]. - It is alleged that the clinical results and regulatory and commercial prospects of botensilimab and balstilimab were misrepresented, leading to materially false and misleading public statements by the Company [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until November 5, 2024, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [2]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [2]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [3]. - The firm has over 70 employees and extensive expertise in complex securities litigation [3].